Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $25.3 million.

  • Aclaris Therapeutics' Cash & Equivalents fell 47.00% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year decrease of 47.00%. This contributed to the annual value of $24.6 million for FY2024, which is 38.39% down from last year.
  • Per Aclaris Therapeutics' latest filing, its Cash & Equivalents stood at $25.3 million for Q3 2025, which was down 0.57% from $25.4 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Cash & Equivalents registered a high of $113.4 million during Q2 2021, and its lowest value of $22.8 million during Q2 2024.
  • For the 3-year period, Aclaris Therapeutics' Cash & Equivalents averaged around $33.3 million, with its median value being $31.1 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first spiked by 248.14% in 2021, then plummeted by 54.37% in 2023.
  • Quarterly analysis of 5 years shows Aclaris Therapeutics' Cash & Equivalents stood at $27.3 million in 2021, then skyrocketed by 65.55% to $45.3 million in 2022, then fell by 11.92% to $39.9 million in 2023, then crashed by 38.39% to $24.6 million in 2024, then crashed by 47.00% to $25.3 million in 2025.
  • Its last three reported values are $25.3 million in Q3 2025, $25.4 million for Q2 2025, and $30.4 million during Q1 2025.